Health topic

Neuroinflammation

These are reviewed research connections, not a ranked list of remedies. An ingredient can appear here because evidence was uncertain, preclinical, or limited to a specific preparation and setting.

Ailment-to-evidence view

What the reviewed research points to

This order reflects the depth of the reviewed evidence, not which option works best or what anyone should take. Mixed and negative findings stay in the list because they can be more useful than a promising headline.

Early or contextual evidence Early signal

Cordycepin

The study combines behavioral and mechanistic assays, but it remains one small animal experiment using purified cordycepin and has no human clinical outcome.

Studied form
Purified cordycepin at 10 mg/kg/day by gavage for four weeks; not a Cordyceps mushroom supplement
Outcome
Mouse learning and memory, hippocampal pathology, microglial polarization, glycolysis and oxidative phosphorylation, and proposed HKII/PDK2 targets
Evidence
Randomized APP/PS1 mouse experiment with behavioral, tissue, primary-cell, and cell-line mechanism assays
See the evidence and cautions →
How this order is calculated

Evidence syntheses come before individual randomized trials, which come before early human and preclinical work. Sample-size bands add a small amount. Positive, mixed, negative, and safety-only directions do not change the depth score. Study independence is not yet scored, so overlapping reviews must not be counted as separate confirmation.

Connected ingredients

What appears in the current evidence map

Source-linked records

1 reviewed record

Preclinical study Early signal Three groups of 12 mice: wild-type, untreated APP/PS1, and cordycepin-treated APP/PS1

Cordycepin changed microglial metabolism and memory behavior in an Alzheimer's mouse model

Purified cordycepin changed memory behavior and tissue markers in APP/PS1 mice. Experiments in BV2 and primary microglial cells linked the response to increased glycolysis through HKII and increased PDH-mediated oxidative phosphorylation through PDK2. The paper describes HKII and PDK2 as potential targets and notes that binding hypotheses need further verification. This animal-and-cell study does not demonstrate human treatment efficacy or support claims for whole Cordyceps supplements.

What was studied
Purified cordycepin at 10 mg/kg/day by gavage for four weeks; not a Cordyceps mushroom supplement
Setting
Studied alone
Why it ranks here
The study combines behavioral and mechanistic assays, but it remains one small animal experiment using purified cordycepin and has no human clinical outcome.
Limits and cautions
  • The main efficacy experiment used 36 mice, and several tissue assays used only three animals per group.
  • APP/PS1 mouse behavior and induced cell models do not establish efficacy or safety in humans with Alzheimer's disease.
  • The intervention was purified cordycepin, not Cordyceps militaris, Ophiocordyceps sinensis, a fermentation product, or a retail supplement.
  • The paper identifies HKII and PDK2 as potential molecular targets using localization, inhibitor, and metabolic assays; the proposed direct binding modes are hypotheses that the authors state require further verification.
  • The authors reported no conflict of interest and public research funding; those statements do not substitute for independent replication.

Cordycepin and Cordyceps supplements are not FDA-approved to prevent or treat Alzheimer's disease or cognitive impairment.